Using 7HP349 to help patients with solid tumors resistant to anti-PD-1 treatment
7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors
This study is testing a new oral medication called 7HP349 to see if it can help boost the effectiveness of current cancer treatments for patients who haven't responded well to anti-PD-1 therapies, with the hope of improving results while keeping side effects low.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | 7 Hills Pharma, LLC NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10931527 on NIH RePORTER |
What this research studies
This research investigates the use of 7HP349, an oral medication designed to activate specific integrins that play a key role in immune response. The goal is to enhance the effectiveness of existing immunotherapies, particularly for patients who have developed resistance to anti-PD-1 treatments. By combining 7HP349 with standard therapies like ipilimumab and nivolumab, the researchers aim to improve patient outcomes while minimizing side effects. The study has already shown promising results in laboratory models and has progressed through early clinical trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors, particularly melanoma, who have shown resistance to anti-PD-1 therapies.
Not a fit: Patients who do not have solid tumors or those who have not previously received anti-PD-1 treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with solid tumors who currently have limited choices due to resistance to existing therapies.
How similar studies have performed: Previous research has shown that enhancing T cell activity can improve responses to immunotherapy, suggesting that this approach may be promising.
Where this research is happening
Houston, United States
- 7 Hills Pharma, LLC — Houston, United States (Active)
Researchers
- Principal investigator: Marathi, Upendra — 7 Hills Pharma, LLC
- Study coordinator: Marathi, Upendra
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.